1-5 of 5
Robert Bittman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Joshua J. Oaks, Ramasamy Santhanam, Christopher J. Walker, Steve Roof, Jason G. Harb, Greg Ferenchak, Ann-Kathrin Eisfeld, James R. Van Brocklyn, Roger Briesewitz, Sahar A. Saddoughi, Kyosuke Nagata, Robert Bittman, Michael A. Caligiuri, Omar Abdel-Wahab, Ross Levine, Ralph B. Arlinghaus, Alfonso Quintas-Cardama, John M. Goldman, Jane Apperley, Alistair Reid, Dragana Milojkovic, Mark T. Ziolo, Guido Marcucci, Besim Ogretmen, Paolo Neviani, Danilo Perrotti
Journal: Blood
Blood (2013) 122 (11): 1923–1934.
https://doi.org/10.1182/blood-2013-03-492181
Published: 2013
Includes: Supplemental data
Journal Articles

FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34 + Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration

Joshua J Oaks, A. Mukhopadhyay, Ramasamy Santhanam, PhD, S. A Saddoughi, Paolo Neviani, PhD, Jason G Harb, Ph.D, Besim Ogretmen, PhD, Robert Bittman, Ph.D, Ross L Levine, MD, Alfonso Quintás-Cardama, MD, Guido Marcucci, MD, Danilo Perrotti, MD, Ph.D
Journal: Blood
Blood (2011) 118 (21): 2494.
https://doi.org/10.1182/blood.V118.21.2494.2494
Published: 2011
Journal Articles

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

Paolo Neviani, Ph.D, Jason G Harb, Ph.D, Joshua J Oaks, B.S., Christopher Walker, B.S., Ramasamy Santhanam, Ph.D, Carolyn Paisie, B.S., Anna Eiring, Ph.D, Bin Zhang, Ph.D, Bastianella Perazzona, Ph.D, Y. Ma, Charlene Mao, Guido Marcucci, MD, Tessa L. Holyoake, PhD, FRCP, FRCPath, Stefano Volinia, MD, Jorge E. Cortes, MD, Michael A. Caligiuri, MD, Claudia Huettner, Ph.D, Robert Bittman, Ph.D, Ching-Shih Chen, Ph.D, Ralph B. Arlinghaus, PhD, Peter Hokland, MD, DMSC, Denis-Claude Roy, MD, FRCPC, Ravi Bhatia, MD, Danilo Perrotti, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 515.
https://doi.org/10.1182/blood.V116.21.515.515
Published: 2010
Journal Articles

Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders

Joshua J Oaks, A. Mukhopadhyay, Ramasamy Santhanam, S. A Saddoughi, Christopher Walker, Paolo Neviani, Jason G Harb, Y. Ma, Srdan Verstovsek, MD, PhD, Guido Marcucci, MD, Roger Briesewitz, Robert Bittman, Ching-Shih Chen, Alfonso Quintas-Cardama, MD, Besim Ogretmen, Danilo Perrotti, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 775.
https://doi.org/10.1182/blood.V116.21.775.775
Published: 2010
Journal Articles

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

Christopher Walker, B.S., Joshua J Oaks, B.S., Paolo Neviani, Ph.D, Jason G Harb, Ph.D., Ramasamy Santhanam, Ph.D, Y. Ma, Guido Marcucci, MD, James Van Brocklyn, Ph.D, Ching-Shih Chen, Ph.D, Robert Bittman, Ph.D, Danilo Perrotti, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 2901.
https://doi.org/10.1182/blood.V116.21.2901.2901
Published: 2010